Biotech news, white papers, reports, and events from PharmaLeaders. New content daily, on our website and delivered right to your inbox.
Arena’s etrasimod meets primary and secondary endpoints in ulcerative colitis trial Published 20 March 2018 Arena Pharmaceuticals has reported positive topline phase 2 results from the OASIS trial for etrasimod, an investigational, once-daily, orally administered, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the treatment of ulcerative colitis (UC). Patients receiving the 2 mg dose of etrasimod achieved statistically significant improvements versus placebo in the primary, all ... Read More
FDA grants Xtandi priority review for Nonmetastatic CRPC Published 20 March 2018 The US Food and Drug Administration (FDA) has accepted Pfizer and Astellas Pharma’s supplemental New Drug Application (sNDA) for Xtandi (enzalutamide) for a new indication and granted priority review designation. If approved, the sNDA would expand the indication of XTANDI to include men with non-metastatic Castration-Resistant Prostate Cancer (CRPC), based on data from ... Read More
Heron’s pain drug succeeds in phase 3 bunionectomy and hernia repair trials PBR Staff Writer Published 20 March 2018 Heron Therapeutics’ pain drug HTX-011 has succeeded in two phase 3 trials in patients undergoing bunionectomy and hernia repair by meeting all their primary and key secondary points. HTX-011, which is a combination of local anesthetic bupivacaine and anti-inflammatory meloxicam, had produced statistically significant reductions in both pain intensity and need ... Read More
House drops CSRs, reinsurance from spending deal A measure to fund reinsurance and cost-sharing reductions has stalled after months of political wrangling as U.S. House of Representatives lawmakers scramble to agree on text for the mega-spending bill that was expected to drop early Monday evening. Republican congressmen Monday night blamed Democrats for the breakdown of negotiations on healthcare provisions in the spending omnibus ... Read More
The Case for Intelligent Design (and Infrastructure) in Life Science Biologics R&D New White Paper from IDC Health Insights examines industry trends, new challenges and emerging capabilities in biologics. With many recent blockbuster patents expiring, the pharmaceutical industry finds itself in the middle of a transformation. Leading life science organizations are updating their business strategies to include the pursuit of a new market opportunity – the discovery and development ... Read More
04/18/2018 - 04/20/2018
|18th Annual DTC National Conference|